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The aim of this study was to compare the cost-utility of the first available single-pill triple combination antihypertensive
therapy containing valsartan (V), amlodipine (A) and hydrochlorothiazide (H), with each of the same components dual
combinations in patients with moderate to severe hypertension.
A Markov model with eight health states was constructed. The short-term effect of antihypertensive treatment
on blood pressure was extrapolated through the Hellenic SCORE and Framingham risk equations, estimating
the long-term survival and quality-adjusted life-years (QALYs) saved. Costs and outcomes were evaluated over
lifetime, divided into annual cycles and discounted at 3.0 % with 2013 as reference year. The analysis was
conducted by the Greek third-party-payer perspective.
The triple combination treatment cost was estimated at €16,525 compared to €15,480 for V/A, €14,125 for V/
H and €11,690 for A/H. The QALYs saved with the triple combination were 12.76 vs. 12.64, 12.61 and 12.38
for double combinations respectively. The incremental cost-effectiveness ratio of the triple combination versus
V/A and A/H was far lower than the Greek GDP per capita (€8,690/QALY and €12,695/QALY, respectively) and
really close for V/H (€16,192/QALY), suggesting V/A/H combination to be cost-effective. Extensive sensitivity
analyses confirmed the robustness of the results. The probability that the triple combination is cost effective
was more than 90 % at a willingness-to-pay threshold of €18,000/QALY.
This is the first study to evaluate the cost-utility of a single-pill triple combination. The single-pill V/A/H therapy is a
cost-effective antihypertensive choice for the treatment of moderate to severe hypertension, compared to its dual
components.
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Hypertension is the most common chronic disease in
the Western world; its prevalence in the adult popula-
tion is higher than 25 %, and is estimated to increase by
30 % by 2025 [1, 2]. Furthermore, hypertension is a
major risk factor for cardiovascular disease (CVD) (includ-
ing coronary artery disease, heart failure and stroke),
chronic kidney disease (CKD) and overall mortality [3–5].* Correspondence: panstafylas@gmail.com
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creativecommons.org/publicdomain/zero/1.0/Thus, elevated blood pressure (BP) is characterized as the
primary attributable risk for death worldwide, accounting
for approximately 7.5 million deaths (12.8 % of the total of
all deaths) and 57 million disability-adjusted life years
(DALYs) according to the World Health Organization
(WHO) [6]. Extensive evidence suggests that antihyper-
tensive treatment significantly reduces cardiovascular
morbidity and mortality. At the same time, co-ordinated
efforts in different countries have led to significant im-
provements in hypertension awareness and treatment
rates; however, BP control rates remain low and unaccept-
able, particularly in Europe [3].rticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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have been proposed, among which inappropriate treat-
ment regimens (i.e., absence of combination treatment,
inadequate doses or inappropriate combinations) and
poor adherence to treatment appear to be the most im-
portant [3, 7]. Therefore, current guidelines recommend
immediate initiation of drug treatment in individuals
with grade 3 hypertension alone or with grade 2 hyper-
tension combined with 3 or more additional risk factors
simultaneously with lifestyle changes [3]. Initiation of
combined drug treatment and prompt up-titration is
advisable for individuals with high CVD risk. When
three drugs are required, the most rational combination
appears to be a renin–angiotensin system blocker, a
dihydropirydine calcium antagonist, and a diuretic at
effective doses [8]. Furthermore, since regimen complex-
ity is a major reason for poor compliance [7, 9], current
recommendations advocate the use of fixed-dose single-
pill combinations to improve BP control rates [3].
In November 2009, the European Medicines Agency
(EMEA) approved the first single-pill, triple combination
of amlodipine (A), valsartan (V) and hydrochlorothiazide
(HCTZ, H), and several months later another triple
combination with olmesartan, amlodipine and HCTZ
was approved. The combination of V/A/H has shown
[10] to be particularly potent and safe in moderate and
severe hypertension. In Greece, where 25 %-30 % of the
adult population are hypertensive, but less than one
third of them are controlled [11], V/A/H constitutes, at
the time this study was conducted, the first available
single-pill triple antihypertensive combination but also
the most expensive antihypertensive pill in the Greek
pharmaceutical market.
Greece among other countries, especially in Southern
Europe, is experiencing a very difficult economic situ-
ation and there are various austerity measures that will
be implemented in the pharmaceutical sector. These
measures aim to reduce the country’s annual pharma-
ceutical bill to less than 2 billion Euros. As the cost-
effectiveness of this new V/A/H combination is totally
unknown, there may be some arguments about whether
it should be reimbursed by third-party-payers. Therefore,
the aim of this study was to evaluate the cost-effectiveness
of the single-pill combination V/A/H against each of the
dual combinations deriving from the same components in
patients with moderate to severe hypertension.
Methods
A Markov model evaluating the cost-utility and the cost-
effectiveness of the single-pill triple antihypertensive
therapy V/A/H against each of the dual components was
constructed. The short-term effect of antihypertensive
treatment on BP was extrapolated through the use of
predictive modelling in order to estimate the long-termsurvival [12]. The analysis was conducted by the Greek
third-party-payer perspective, the recently founded
National Organization for the Provision of Health
Services (EOPYY), which covers the health expendi-
tures of more than 90 % of Greek citizens. An annual
discounting rate of 3 % was used for effectiveness and
cost estimations [13].
Overview of model structure
The structure of the model is illustrated in Fig. 1. In par-
ticular, this model consists of eight states of health status
in respect of cardiovascular morbidity and mortality:
“Healthy” with hypertension, angina, acute myocardial
infarction (AMI), post AMI, stroke, post-stroke, congest-
ive heart failure (CHF) and death from cardiovascular or
other cause. A particular cost and quality of life (QoL)
value is assigned to each health state. Each arrow repre-
sents a transition from one health state to another,
which can occur with a certain probability at yearly in-
tervals. In general, patients enter the model in the
“healthy with hypertension” state and can experience
one of the following events during each model cycle:
death, angina, AMI, stroke or CHF. Patients experien-
cing angina can move into AMI, stroke, CHF or death.
Patients experiencing a CHF event can only die during
the following model cycles; otherwise they remain in the
same state. Patients experiencing an AMI or stroke
spend one year in an interim state, before transitioning
to the post-AMI or post-stroke state. Only patients that
do not die during this first year make a transition to the
“Post MI” and “Post stroke” states. These states are very
similar to the “AMI” and “stroke” states. However, the
main idea behind this specific construct of the Markov
model is to allow for a worse prognosis and higher cost
in the first year after a non-fatal event compared with
the second and subsequent years. Patients at the state of
“post-MI” (or “post-stroke”) may experience a recurrent
event and then transit to the AMI state (or “stroke”), or
experience another non-fatal (i.e., angina, CHF, stroke)
or fatal event. The model runs up to the time that it can
be assumed that all patients are dead. The model was
developed in Microsoft Excel 2003.
Model inputs
Comparators, doses and treatment effect
In the present study the single-pill triple treatment of V/
A/H 320/10/25 mg was compared with each of the dual
components: V/H 320/25 mg, V/A 320/10 mg and A/H
10/25 mg. The treatment measure was the mean reduc-
tion in systolic blood pressure (SBP), which was extracted
from the only head-to-head clinical trial published in 2009
demonstrating a 39.7, 32.0, 33.5 and 31.5 mmHg reduc-
tion for the V/A/H, V/H, V/A and A/H combinations












Fig. 1 A graphical presentation of the Markov model
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The probabilities for experiencing a fatal or non-fatal
cardiovascular event (transition probabilities) were cal-
culated based on the post-treatment blood pressure,
which is incorporated in the risk equations of Hellenic
SCORE and Framingham, along with other relevant
parameters. The Hellenic SCORE risk equation was used
to calculate the 10-year cardiovascular death risk, which
was subsequently transformed into the corresponding
annual probability [15]. The Framingham risk equation
was used to calculate the annual probability of experien-
cing an AMI, angina, CHF, stroke as well as subsequent
non-fatal AMI and angina [10, 16–19]. The annual prob-
ability for a subsequent stroke event was extracted from
the most recent NICE guideline on hypertension [20]
due to lack of relative predictive equations. TransitionTable 1 Summary of demographic and clinical input parameters ap
Characteristic Value
Mean age (SD), years 53.2 (1
Male (%) 55.3
Mean SBP (SD), mmHg 169.9
Mean DBP (SD), mmHg 106.5
Male smokers (% of males) 51 %
Female smokers (% of females) 39 %
Male diabetics (% of males) 11.2 %
Female diabetics (% of females) 10.5 %
Total cholesterol (mmol/L) 5
HDL cholesterol (mmol/L) 1.25
Body mass index (kg/m2) 27
Abbreviations: SBP systolic blood pressure, DBP diastolic blood pressureprobabilities for non-cardiovascular death were esti-
mated by using the Greek mortality rates based on the
latest data of the Hellenic Statistical Authority [21].Baseline population
The demographic and baseline characteristics of the tar-
get population are described in Table 1. It was assumed
that the Greeks had a low cardiovascular risk profile
based on epidemiological data [22–24]. The “High” and
“Low” risk refer to the two risk regions of the European
population, which exhibit the highest and lowest risk for
developing cardiovascular diseases. The former includes
countries such as Russia, Bulgaria and Latvia, while the
latter includes countries such as Greece, Sweden, France
and Germany [22].plied in the baseline model
Reference
0.3) Calhoun et al. (2009) [10]
Calhoun et al. (2009) [10]
(14.1) Calhoun et al. (2009) [10]
(5.1) Calhoun et al. (2009) [10]
Pitsavos et al. (2003) [23]
Pitsavos et al. (2003) [23]
WHO (accessed 11/2013) [24]
WHO (accessed 11/2013) [24]
Pitsavos et al. (2003) [23]
Pitsavos et al. (2003) [23]
Pitsavos et al. (2003) [23]
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Due to lack of utility values for the Greek population
under evaluation, health utilities were extracted from
recent published studies and reviews that have already
been applied to similar Greek populations [25]. QALYs
were calculated based on the above utility weights,
whereby the assumption applied was that patients
experiencing an event have constant utility for the whole
duration of one year (Table 2).Costs calculation
In the present model, only direct health care costs were
taken into consideration. The total state-specific cost
was calculated based on the costs of hospitalisation, out-
patient visits, concomitant medications, laboratory and
imaging diagnostic examinations (Table 3) as well as the
cost of antihypertensive treatment (Table 4). The cost
derived from the treatment of adverse events was not
considered in this analysis because there were no statis-
tical differences among the different treatment choices
[10]. The hospitalisation cost was estimated based on
the Diagnostic Related Groups (DRGs). This cost was
obtained from the Government Gazette issued in March
2012 by the Ministry of Health. The rest of the cost
components were calculated by multiplying the number
of units for each resource (i.e., number of outpatient
visits) by the corresponding unit cost available from the
Government Gazette. The unit costs data correspond to
the year 2013. For the estimation of patient-level antihy-
pertensive medication costs, the daily dose of each drug
was combined with the relevant price obtained from the
bulletin issued by the Greek Ministry of Health. The an-
nual cost of each comparator medication was calculated
based on the assumption that patients would take the
same daily dose of each drug, every day throughout the
year, until they experience a fatal event.Table 2 Utilities used in the model (Maniadakis et al. 2011 [25])
Age Healthy/HTN Angina/AMI/Post AMI
Men Women Men Women
20 0.91 0.88 0.84 0.81
25 n.a. n.a. n.a. n.a.
30 0.90 0.86 0.83 0.79
40 0.86 0.85 0.79 0.78
46 n.a. n.a. n.a. n.a.
50 0.84 0.82 0.77 0.75
60 0.83 0.78 0.76 0.71
65 n.a. n.a. n.a. n.a.
70 0.81 0.78 0.74 0.71
80 0.74 0.74 0.67 0.67
Abbreviations: AMI acute myocardial infarction, HTN hypertension, N/A non-applicabEconomic analysis
The primary outcome was the cost-utility of the triple
antihypertensive treatment over comparators, calculating
the incremental cost effectiveness ratio (ICER) of Euros
per quality-adjusted life years (QALY) saved. Secondary
outcomes included QALYs saved, life-years gained
(LYG), total cost for each comparator and the ICER per
LYG. In general, when V/A/H is associated with higher
effectiveness and higher cost, it is considered highly
cost-effective when the ICER is lower than the Gross
Domestic Product (GDP) per capita of the country, cost-
effective when the ICER is one to three times higher
than the GDP per capita and non cost-effective when
the ICER is higher than three times the GDP per
capita – a specific predetermined threshold recom-
mended by the World Health Organization [26, 27].
According to the International Monetary Fund (IMF),
the GDP per capita in Greece has been estimated at
€16,303 for 2013 [28].
The majority of input data used in the current model
are subject to variation. Therefore, in order to overcome
the issue of uncertainty, a probabilistic sensitivity ana-
lysis was conducted. Probability distributions were se-
lected based on the nature of variables [29]. For costs,
the logarithms were assumed to be normally distributed.
In general, the distribution parameters were estimated
based on mean and standard deviations (SD) of pub-
lished data (if available), whereas in case information on
parameters variability was unavailable, their standard de-
viation was assumed to be equal to 10 % of the mean.
Following this, 5000 estimates of costs, LYs, QALYs,
and incremental cost per QALY saved and per LYG (life
year gained) were obtained by applying the bootstrap-
ping technique. The bootstrap percentile method was
used to obtain the uncertainty appropriate intervals for
each parameter, as described elsewhere [30]. The results
are presented as mean (95 % uncertainty interval). AStroke/Post-stroke Heart Failure
Men Women Men Women
0.82 0.79 n.a. n.a.
n.a. n.a. 0.69 0.63
0.81 0.77 n.a. n.a.
0.77 0.76 n.a. n.a.
n.a. n.a. 0.61 0.56
0.75 0.73 n.a. n.a.
0.74 0.69 n.a. n.a.
n.a. n.a. 0.57 0.52
0.72 0.69 n.a. n.a.
0.65 0.65 n.a. n.a.
le
Table 3 Cost of health resources used in the baseline model
(in Euros, €)



















Heart Transplantation Ε05Α 34,000









Blood and Biochemistry Testsc 57.40
Treadmill Stress Test 28.11
Abbreviations: CHF congestive heart failure, PCI percutaneous coronary
intervention, CABG coronary artery bypass graft, ICD implantable cardioverter-
defibrillator, CRT cardiac resynchronisation therapy, CT computed tomography,
MRI magnetic resonance imaging, MRA Magnetic Resonance Angiography
aHospitalisation costs derive from the Government Gazette issued in March
2012 by the Ministry of Health; cost of death is extracted from Maniadakis
et al. 2005 [37] and CRT cost is obtained from a Government Gazette
published in 2007
bClinical, laboratory and imagining examination costs are obtained from a
Government Gazette that is valid in November, 2013
cRoutine laboratory tests include blood count, urine test, test for levels of
glucose, urea, creatinine, sodium, potassium, SGOT (serum glutamic-
oxaloacetic transaminase), SGPT (serum glutamic-pyruvic transaminase), CPK
(creatine phosphokinase), total cholesterol, HDL-C (high-density lipoprotein
cholesterol), LDL-C (low-density lipoprotein cholesterol), triglycerides, uric acid
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cating the proportion of simulations according to which
V/A/H is considered cost-effective over its comparatorsat different levels of willingness to pay per effectiveness
unit gained [31].
Sensitivity analyses
In our study, the impact of six assumptions used in the
Markov model was tested in one-way sensitivity analyses
by varying the following data: (1) costs and outcomes
were discounted at 0 % and at 6 %, (2) drugs were
substituted by the cheapest generics, (3) the costs and
the use of other health resources were modified (±50 %),
(4) drug prices were estimated based on alternative sick-
ness fund coverage, and the synthesis of the population
was changed to include (4) patients with different age
groups (40, 60 and 70 years), (5) 100 % patients with
diabetes, and (6) 100 % patients with prior CVD.
Results
Costs
The total discounted cost for participants receiving the
triple combination (V/A/H) was €16,525.25, whereas for
the dual combinations of V/H, V/A and A/H the total
discounted costs were €14,124.74, €15,480.46, €11,690.08
respectively (Table 5). In all combinations, except for A/H,
total costs were made up mainly of drug costs, which
accounted for 41.54 %, 31.60 % and 37.21 % of the overall
costs of V/A/H, V/H, V/A respectively.
Clinical outcomes
Table 6 presents the effectiveness results comparing the
triple single-pill combination (V/A/H) with each possible
dual combination. The analysis showed that the triple
combination was more effective compared to its dual
components for both estimates of QALYs and LYGs.
Patients who received V/A/H gained 12.76 QALYs and
15.99 LYs. Therefore, V/A/H was associated with a gain
of 0.12 to 0.38 QALYs and 0.14 to 0.49 LYs when com-
pared with its dual components.
Cost-effectiveness
The ICER was calculated with respect to the triple
single-pill combination of V/A/H (Table 6). Compared
to the examined dual combinations, V/A/H presented a
cost per QALYs ratio of €16,192.40 when tested against
V/H combination, of 8690.13 against V/A combination
and of €12,694.89 against the A/H combination.
The probabilistic analysis also suggested that V/A/H
is cost-effective compared to V/H, V/A and A/H dual
combinations, since the mean ICER is either slightly
higher or lower than the GDP per capita. For patients
receiving the triple combination, there was an incre-
mental survival benefit (in QALYs) of 0.15 (95 % CI,
0.04-0.26), 0.12 (95 % CI, 0.01-0.23) and 0.38 (95 %
CI, 0.27-0.49) compared to V/H, V/A and A/H com-
binations respectively (Figs. 2a, b, c). Based on the
Table 4 Drug pricesa used in the baseline model (in Euros, €)
Drug name Package (tablets × dose in mg) Retail price per package Daily cost for EOPPY
V/A/H brandedb 28 × 320/10/25 43.84 1.17
V/A brandedb, c 28 × 160/5 26.50 1.42
V/H branded 14 × 320/25 14.42 0.77
V/H generic 14 × 320/25 10.96 0.59
Valsartan branded 14 × 320 11.77 0.63
Valsartan generic 28 × 320 13.86 0.37
Amlodipine branded 14 × 10 6.78 0.36
Amlodipine generic 30 × 10 9.69 0.24
Hydrochlorothiazide 20 × 25 0.69 0.03
aDrug prices were obtained through the Government Gazette published by the Greek Ministry of Health and are expressed in 2013 values (€)
bNo available generic for V/A/H and V/A combinations; not available A/H combination neither in branded nor generic form
cNo available package at 320/10 mg; therefore two tablets per day were necessary to reach the same strength
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the triple combination to be cost-effective at a
willingness-to-pay threshold of €18,000/QALY (Fig. 3).
Sensitivity analyses
Table 7 depicts our sensitivity analyses. Our results were
shown to be robust for the six variables we evaluated in
one-way sensitivity analyses. In most cases, the single-
pill combination was proven to be a cost-effective
choice, since the ICER value was lower than €20,000/
QALY and usually lower than the GDP per capita.
In the case of generic substitution, although the
single-pill triple combination remained more costly (due
to drug costs) compared to the other dual combinations,
it was still cost-effective in comparison with the cheapest
generic combinations. By examining fluctuations in the
prices of generics, we determined that V/A/H ceases to
be cost-effective only in the case of a generic drug price
reduction of 75 % and above.
Discussion
The present study is the first cost-effectiveness analysis
of a single-pill triple antihypertensive combination ver-
sus its dual components. This analysis was performedTable 5 Total Costs per Category (values in Euros (€)
Cost Category V/A/H V/H A/V A/H
Drugs 6863.94 4464.02 5760.68 2206.07
Other Medication 1732.86 1733.97 1773.32 1690.92
Hospitalisation 2567.05 2613.56 2621.59 2560.13
Outpatient Visits 400.32 402.42 403.43 394.44
Vascular Interventions 1818.07 1779.99 1785.88 1743.21
Laboratory Exams 2572.37 2552.66 2558.97 2501.37
Death 570.62 578.11 576.59 593.94
Total Costa 16,525.25 14,124.74 15,480.46 11,690.08
aAdding up the values for each combination might differ from the total cost
value due to roundingfrom the perspective of the Greek third-party payer,
which is currently covering the healthcare expenditures
of more than 90 % of the Greek population. The clinical
effectiveness of all comparators was based on the results
of the only head-to- head clinical trial available to date
[14]. Using a Markov model and assuming that the
beneficial effects of the triple combination and the
respective comparators would be maintained while pa-
tients remain on these drugs, we estimated that the triple
single-pill combination would be expected to increase life
expectancy by 0.14 to 0.49 years and QALYs by 0.12 to
0.38 in comparison with its dual components. We also
observed that the ICER for V/A/H in the main analysis in
comparison with the three dual combinations under
examination (A/H, V/H and V/A) was lower than the
Greek GDP per capita. These results suggest that although
the triple combination is the most expensive antihyperten-
sive pill in Greece, it is also a cost-effective choice among
patients with grade 2 and 3 hypertension.
In the present study, we also conducted a probabilistic
analysis and extensive sensitivity analyses modifying the
most important input parameters in order to test the
robustness of our results. There was a probability of
more than 90 % for the triple combination to be cost-
effective at a willingness-to-pay threshold of €18,000/
QALY. The results of these analyses were particularly
stable in modifying the input parameters regarding the
prevalence of diabetes and the incidence of prior CVD.
The results remained constant in different age groups;
however the ICER was lower in younger hypertensive
patients reflecting the higher lifetime risk of cardiovas-
cular adverse events and the importance of hypertension
control in younger ages. The modification of the health
resources cost (±50 %) did not change the results signifi-
cantly, nor did the estimation of the daily drug cost for
the third-party payer by using an alternative sickness
fund coverage method that has recently been intro-
duced and is based on the following formula: Daily
Table 6 Baseline deterministic cost, effectiveness and cost-effectiveness results comparing the triple single-pill combination (V/A/H)
with each possible dual combination
Treatment alternative Cost (€) Incremental Cost (€) Effectiveness (QALYs/LYs) Incremental effectiveness (QALYs/LYs) ICER (€/QALY or €/LY)
In QALYs
V/A/H 16,525.25 12.76
V/H 14,124.74 2400.51 12.61 0.15 16,192.40
V/A 15,480.46 1044.79 12.64 0.12 8690.13
A/H 11,690.08 4835.17 12.38 0.38 12,694.89
In LYs
V/A/H 16,525.25 15.99
V/H 14,124.74 2400.51 15.81 0.18 7456.95
V/A 15,480.46 1044.79 15.85 0.14 4073.82
A/H 11,690.08 4835.17 15.50 0.49 5002.20
Abbreviations: V valsartan, H hydrochlorothiazide, A amlodipine, QALY quality-adjusted life year, LY life year, ICER incremental cost-effectiveness ratio
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(Retail Price – Sickness Fund Price)]. Finally, the sub-
stitution of the branded drugs by the cheapest avail-
able generics maintained the cost-effectiveness of the
triple combination, despite the increase in the ICER
values. The analysis showed that for V/A/H not to be
cost-effective, generic prices should fall further by at
least 75 %.
Suboptimal antihypertensive regimens, including ab-
sence of treatment intensification or inappropriateFig. 2 Cost-effectiveness plane for V/A/H versus V/H (a), V/A (b) and A/H (ccombinations have long been considered a main rea-
son for the poor control rates of hypertension in
many countries [3, 7]. It has also been documented
for a long time that a large proportion of patients
presenting treatment-resistant hypertension, in reality,
either receives improper combinations or is poorly
compliant with the prescribed treatment [32]. For pa-
tients requiring more than two drugs to be con-
trolled, a combination of a renin–angiotensin system

















Probability to be cost-effective = 91.2% at a 
ICER Threshold in /QALY
willingness-to-pay threshold of 18,000/QALY
V/A/H vs V/H V/A/H vs V/A V/A/H vs A/H
Fig. 3 Cost-effectiveness acceptability curve
Table 7 One-way sensitivity analyses (Incremental Cost-Effectiveness Ratio expressed in €/QALY; discounted at 3 %)
Value V/H V/A A/H
Baseline 16,192.40 8690.13 12,694.89
Discount rate
Low: 0 % 9136.23 4899.12 6528.41
High: 6 % 18,887.19 10,127.14 15,888.91
Generic Substitution
Cheapest generics 30,021.13 21,881.33 12,870.17
Marginal price (further price decrease −75 %) 41,707.74 51,015.44 17,685.29
Health resources cost
50 % decrease 16,188.30 8766.81 12,518.28
50 % increase 16,202.98 8620.55 12,875.81
Price estimation based on alternative sickness fund coverage
Deterministic 30,021.13 15,609.78 11,069.45
Probabilistic (mean) 26,105.42 18,295.66 11,298.31
Age group
40 years 12,976.54 7133.45 16,440.77
60 years 19,162.85 10,037.84 11,961.30
70 years 23,846.40 11,883.61 9960.84
Clinical characteristics
All patients diabetics 16,477.38 8711.76 13,137.42
Prior CVD 15,342.43 7966.95 11,985.83
Abbreviations: V valsartan, H hydrochlorothiazide, A amlodipine, CVD cardiovascular disease
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first choice due to proven efficacy and favorable
adverse-effect profile [7, 8].
In addition to the above, it is well-known that
adherence to antihypertensive treatment may fall by
as much as 50 % within the first year [33], and regi-
men complexity is a major reason for this [7, 9]. In-
creased adherence to antihypertensive treatment is
associated with better BP control [34] and reduced
cardiovascular events [35]. Use of fixed-dose, single-
pill combination treatment has recently been shown
to markedly improve patient compliance [36], and
thus, current recommendations advocate the use of
fixed-dose combinations (including triple combina-
tions, when necessary) to improve BP control and
reduce associated morbidity and mortality [3]. Hence,
it is of major importance to stress that this study
probably underestimates the cost-effectiveness of the
triple single-pill combination, as it is expected that a
single-pill formulation would further improve adher-
ence and persistence to treatment, thus leading to
better BP control and reduced cardiovascular compli-
cations, versus comparator treatments including 2 to
3 different pills.
There are some potential limitations to our study.
Since transition probabilities specific to the Greek
population were not available, probabilities for AMI,
angina, CHF, stroke, subsequent non-fatal AMI and
angina were extracted from the Framingham study
and probabilities for subsequent stroke and hyperten-
sion from the relevant NICE guidelines. The utility
values used are also not specific to the Greek hyper-
tensive population and a divergence affecting the out-
comes of the model could be possible. We strongly
believe, however, that no apparent epidemiological
reasons exist for the Greek hypertensive population to
differ from the relevant population of other Western Soci-
eties in the above-mentioned parameters.
To estimate the medication cost we assumed that
patients remain on the same daily dose throughout the
duration of the model; this might not always be the case,
affecting the cost-effectiveness results. Finally, a limita-
tion rather common to modelling analyses is the fact
that QALY results are driven primarily by the cost of the
drugs. We used a sensitivity analysis with generic substi-
tution to address this issue and we found that drug cost
has an impact on our results but did not affect the final
cost-effectiveness profile of the triple single-pill combin-
ation over the dual combinations.
In conclusion, this first cost-effectiveness analysis of
a triple single-pill antihypertensive combination sug-
gests that a triple single-pill combination of valsartan,
amlodipine and hydrochlorothiazide is expected to in-
crease life expectancy and QALYs in comparison witheach of the dual components, and it is also a cost-
effective choice, as its ICER versus the dual combina-
tions was lower than the Greek GDP per capita.
These results were proven robust after an extensive
set of sensitivity analyses. Additionally, the beneficial
effects of increased compliance following a single-pill
combination may in reality increase the cost-effectiveness
of the triple combination. Further studies in different set-
tings or with different triple single-pill combinations are
awaited to shed more light on this field.
Perspectives
Overall, the single-pill triple combination fulfills all
the current guideline recommendations for patients
with grade 2 and 3 hypertension or high cardiovascu-
lar risk as it is one of the most effective antihyperten-
sive pills in reducing SBP and DBP, it allows early
initiation of combination therapy and is the most
rational combination, containing a blocker of RAAS,
a calcium antagonist and a diuretic at effective doses.
Moreover, it is the first available single-pill triple
combination antihypertensive therapy and one of the
three approved by the EMEA. The above in addition
to the cost-effectiveness nature of the drug indicated
by the results of our study, render the triple combin-
ation a preferable choice for the treatment of grade 2
and 3 hypertension.
Novelty and Significance: 1) What Is New, 2) What Is
Relevant?
1. What Is New?
The present study constitutes the first
cost-effectiveness analysis of a triple
single-pill combination for the management
of high blood pressure versus its dual
components.
2. What Is Relevant?
Recent treatment guidelines clarify the
preference for single-pill combinations
since they increase treatment adherence,
improve patient compliance and therefore,
reduce morbidity and mortality associated
with inadequate blood pressure control.
Therefore, it is of great importance to
perform an economic evaluation for such
a triple combination in order to examine its
cost-effectiveness and determine whether it
should replace current treatments or not.
Due to the present economic situation,
extra light should be shed on such a
cost-effectiveness analysis as its results
might lead to long-term cost-savings within
healthcare budgets.
Stafylas et al. Cost Effectiveness and Resource Allocation  (2015) 13:10 Page 10 of 113. Summary
The results of our study showed that the
single-pill triple combination is cost-effective
compared to its dual components, rendering it
a preferable choice for the treatment of grade
2 and 3 hypertension.
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